# Best AI Directions for the CBR Healthy Brain Aging Challenge

## The strongest project thesis

The best fit for a team of B.Tech. computer science graduates with a bioinformatics specialisation is a **multimodal longitudinal risk-and-progression workbench** built on **structured features** rather than a raw-image foundation model. The core product should do three things together: **harmonise cohort data**, **predict future cognitive decline or conversion to MCI/dementia**, and generate a **“digital twin lite” trajectory forecast** for each participant with uncertainty bands. That matches the challenge brief almost exactly, because the organisers explicitly call for models and tools such as prediction of MCI/dementia, disease progression, digital twins, and data processing or harmonisation, and the challenge data are described as multimodal and already include extracted or tabulated MRI and OCT/Angio parameters, cognitive assessments, blood biochemistry, and omics. It is also the most realistic route for a student team because it uses the strongest part of the available data without requiring a compute-heavy attempt to train raw 3D imaging models from scratch. citeturn7search0turn23search0turn15view3turn15view4

This is also where the scientific field is moving. A recent systematic review in *JMIR* found that multimodal AI models generally outperform single-modality approaches for Alzheimer’s diagnosis, prognosis, and risk prediction, but also warned that performance is often hard to trust because datasets, outcome definitions, and validation practices vary widely. That makes a **benchmarked, externally validated, harmonisation-aware system** more valuable than yet another one-off classifier. citeturn28view0turn29view0

A full biological or treatment-response digital twin is still an early and ambitious area in dementia research. Reviews and trial-methodology papers suggest digital twins may become useful for modelling trajectories and improving trial efficiency, but for a competition build, the feasible version is a **personalised longitudinal simulator** that forecasts likely future cognitive scores, biomarker shifts, or risk transitions under observed trajectories rather than claiming causal treatment effects. That is ambitious enough to look innovative and grounded enough to be believable. citeturn24search0turn24search1turn24search11

## The data landscape and why the CBR cohorts matter

The public dataset stack is unusually strong. **ADNI** is the classic longitudinal multimodal benchmark for Alzheimer’s work, with clinical, imaging, biomarker, cognitive, genetic, and demographic data. **NACC** is extremely valuable for large-scale longitudinal clinical phenotype modelling and now exposes neurocognitive, imaging, genetic and genomic, neuropathology, fluid biomarker, and pilot data streams, with more than 56,000 participants and over 25 years of data. **AIBL** adds an ageing-focused Australian cohort with repeated assessments every 18 months across biomarkers, neuroimaging, cognition, mood, health, and lifestyle. **OASIS** is especially useful for quick experimentation because it is openly accessible and includes both cross-sectional and longitudinal MRI datasets; the project notes that its releases have already been used for segmentation algorithms and imaging analyses, and OASIS-3 is a longitudinal multimodal dataset for normal ageing and Alzheimer’s disease. **UK Biobank** is different from the dementia cohorts because it is population-scale: its imaging programme has reached 100,000 whole-body scans and combines imaging with genetics and lifestyle, which makes it ideal for preclinical risk work, brain-age style modelling, and low-cost biomarker discovery. **ADDI** adds a data-discovery and cloud-analysis layer rather than a single cohort, giving access to a free, secure workbench and a discovery portal spanning imaging, omics, clinical, and multimodal datasets. citeturn15view0turn31view0turn15view1turn15view8turn30view0turn15view7turn15view9turn16view0

The CBR cohorts are what make this challenge genuinely differentiated. **TLSA** is an ongoing urban ageing cohort in Bengaluru that began in 2015 with the aim of recruiting 1,000 older adults for long-term follow-up. **SANSCOG** is a large rural ageing cohort in Kolar district, enrolling healthy adults aged 45 years and older with a projected size of 10,000. Together, they create something the public datasets do not: a long-horizon **India-specific, rural-versus-urban, multimodal ageing platform** for dementia research. Because the challenge explicitly states that participants are encouraged to use the major global public datasets extensively and then combine them with multimodal CBR data, the winning strategy is not “public data or CBR data”; it is **public pretraining and benchmarking plus CBR adaptation and Indian validation**. citeturn15view3turn15view4turn7search0turn23search0

**GenomeIndia** is the other major advantage. CBR’s own GenomeIndia page and the official project site make the case clearly: Indian populations are highly diverse, historically underrepresented in global genomic databases, and disease findings from other populations cannot simply be extrapolated to Indians. The project has already sequenced roughly 10,000 whole genomes from 83 populations and is designed to support open or controlled-access genomic analysis, better disease gene discovery, and more accurate risk prediction for Indian populations. For a dementia challenge, that means your team can build an **ancestry-aware genomics module** instead of blindly importing European-derived polygenic ideas. citeturn15view5turn26view0turn26view1turn14search3

**YLOPD** should not be treated as Alzheimer’s training data, because it is a Parkinson’s cohort, but it is still strategically useful. CBR describes it as a longitudinal neurodegeneration study designed to recruit 1,000 patients and follow them over time, and CBR materials describe it as using multimodal evaluation including brain and retinal imaging plus genomics. That makes it a good **pipeline-transfer testbed** for reusable cohort tooling, multimodal QC, longitudinal visit handling, and omics infrastructure, even if it should stay outside the main dementia target model. citeturn15view6turn4search10

## High-value builds for a B.Tech. bioinformatics team

The **best flagship build** is a **CBR Dementia Progression Studio**. Its first layer is a harmonisation engine that aligns variables across ADNI, NACC, AIBL, OASIS, UK Biobank, TLSA, and SANSCOG into one analysis-ready schema. Its second layer is a risk engine that predicts outcomes such as incident MCI, incident dementia, or meaningful decline on cognitive scales. Its third layer is a patient-level forecast view that shows likely future trajectories over the next one, three, and five visits. This idea fits the challenge, uses your team’s strengths in data engineering, ML, and bioinformatics, and addresses a real field bottleneck: recent Alzheimer’s AI literature keeps noting that multimodal integration is powerful, but harmonisation, validation quality, and cohort heterogeneity remain major problems. citeturn7search0turn23search0turn28view0turn11search12

A **retina-first low-cost triage model** is the best secondary idea if you want a sharper India or public-health angle. The challenge data specifically mention OCT and Angio-derived parameters, and recent literature keeps treating retinal measures as promising non-invasive biomarkers for Alzheimer’s and cognitive decline. The important nuance is that the evidence is promising but not fully standardised, so the right product is not “eye scan diagnoses dementia,” but rather “eye plus cognition plus blood features improve early risk triage.” That makes it scientifically safer and far more defensible for judges. citeturn23search0turn20search1turn20search7turn20search13

A **harmonisation and cohort query tool** is more important than it sounds, and it may actually be one of the smartest competition moves. NACC’s platform is built around FAIR data, secure sandboxes, and multimodal discovery. ADDI’s Discovery Portal exists because dataset discovery and interoperability are still painful. Recent AI-focused Alzheimer’s reviews explicitly describe harmonisation challenges as foundational, from syntax differences to cohort-specific variable definitions. A tool that maps variables, normalises units, aligns visit times, tracks missingness, and creates reproducible cohort extracts could score very well because it is useful even before a single model is trained. citeturn15view10turn16view0turn11search12

A **genomics-aware risk calibration module** is where your bioinformatics specialisation can stand out. Instead of trying to build a full disease-gene discovery paper inside a competition, the practical move is to create pathway-level, burden-level, or ancestry-aware genomic features that improve prediction or uncertainty estimation. GenomeIndia now provides exactly the kind of population-aware reference backdrop that makes this credible for Indian cohorts, and its own FAQ explicitly notes that current risk models often perform poorly in non-European populations. citeturn26view1turn26view0turn14search3

What I would **not** make the centrepiece is a raw MRI-only CNN, a generic LLM medical chatbot, or a genetics-only polygenic risk score. The challenge is broader than diagnosis alone, the provided data are already structured for multimodal modelling, and the strongest recent reviews keep stressing that clinical translation depends on multimodal design, transparent evaluation, and real generalisability rather than a narrow benchmark score. citeturn23search0turn28view0turn29view0

## A practical technical blueprint for the recommended build

The data model should be longitudinal from day one. Do not store everything in a single flat table. Create a **participant table**, a **visit table**, a **modality-feature table**, an **outcome-event table**, and a **metadata dictionary** that records units, feature provenance, and missingness codes. Because the challenge data are described as extracted or tabulated MRI and OCT variables plus cognitive, blood, and omics data, this structure will let you start with analysis-ready models immediately and still remain compatible with future raw-data expansion. citeturn23search0turn15view3turn15view4

Your baseline models should be simple and strong before anything fancy: logistic regression, penalised Cox models, random survival forests, and gradient boosting for incident-risk tasks; linear mixed-effects models or gradient-boosted regressors for future score prediction. Then add one advanced longitudinal model that can handle irregular visits and missingness, such as a GRU-D style sequence model, temporal transformer, or latent state-space model. The point is not to impress judges with architecture jargon; it is to show that your advanced model clearly beats a transparent baseline and still remains calibrated and interpretable. That matters because recent systematic evidence shows multimodal gains are real, but also that high headline metrics from curated cohorts can be misleading without rigorous validation. citeturn28view0turn29view0

Outcome definition needs discipline. Use endpoints that map cleanly to established Alzheimer’s staging language: cognitively unimpaired to MCI, MCI to dementia, future cognitive decline, and possibly progression subtype discovery. The Alzheimer’s Association’s revised 2024 criteria place strong emphasis on biological staging and biomarker-informed diagnosis, while still warning that biomarker-based evaluation of cognitively unimpaired individuals is currently for research contexts rather than general clinical care. For a competition build, that means your language should be **risk stratification for research and monitoring**, not “screening healthy people for clinical diagnosis.” citeturn25view0

For fusion, favour **modality-aware late fusion** or **missing-aware attention/gating** rather than a brittle all-or-nothing model. Multimodal Alzheimer’s datasets are rarely complete, and missingness is a core challenge in this literature. A model that degrades gracefully when one modality is absent is more valuable than a model that needs every feature block filled. You can also add calibration, uncertainty intervals, and SHAP-style explanations to make the results usable for researchers rather than just numerically strong. citeturn11search1turn28view0

The public-data-first strategy should be explicit. Use **OASIS** for fast prototyping, **ADNI** for multimodal longitudinal benchmarking, **NACC** for structured clinical generalisation, **AIBL** for external ageing-cohort validation, and **UK Biobank** for preclinical blood and population-risk experiments. Then adapt or fine-tune the learned feature interfaces on **TLSA** and **SANSCOG**. This lets you show both scientific maturity and practical use of the organisers’ invitation to leverage public datasets extensively. citeturn30view0turn15view0turn31view0turn15view1turn15view7turn7search0

Your bioinformatics module should focus on **genomic features that are realistic in small-to-medium cohorts**: ancestry principal components, pathway enrichment scores, rare-variant burden summaries, pharmacogenomic flags where relevant, and Indian-reference-aware variant filtering. GenomeIndia’s own material makes clear that Indian population structure and population-specific variants matter for risk prediction and diagnosis, so even a modest genomics layer can become a strong differentiator if you keep it disciplined and population-aware. citeturn26view1turn26view0

## Execution, judging risks, and what to avoid

A good student team can absolutely build this if roles are split cleanly: one person on data engineering and harmonisation, one on modelling baselines and evaluation, one on longitudinal or survival modelling, one on genomics and omics features, and one on product-demo work such as dashboards, documentation, and reproducibility. What makes this realistic is that the challenge data are already described as structured multimodal features, not a requirement to derive everything from raw scans. citeturn23search0

The main judging risk is **overclaiming**. Recent reviews in the field repeatedly warn that multimodal Alzheimer’s models can look excellent on internal or curated datasets but become much less impressive under external validation, heterogeneous cohorts, and real-world deployment conditions. Your submission should therefore lead with **external validation, subgroup analysis, calibration, confidence intervals, and transparent reporting**, not just AUROC. If you do that well, you will immediately look more serious than many technically flashy but weakly validated entries. citeturn28view0turn29view0turn19search10turn19search1

The second risk is **label leakage and visit leakage**. In longitudinal dementia work, it is easy to accidentally let future information leak into current predictions through subject-split mistakes, visit ordering mistakes, or selecting variables that already encode late-stage diagnosis. The safest practice is participant-level splitting, time-aware feature windows, strict train-validation-test separation by person, and at least one truly external cohort test. The recent *JMIR* review explicitly warns that headline metrics should often be treated as upper bounds unless they are backed by external validation and transparent reporting. citeturn28view0turn29view0

The third risk is **using genomics badly**. A European-style risk score copied into Indian cohorts without recalibration is exactly the sort of shortcut that GenomeIndia was created to move beyond. Your genomics layer should therefore improve model fit, uncertainty estimation, or biological interpretation, but it should not dominate the submission unless you have enough sample size and rigorous validation to support it. citeturn26view1turn14search3

The fourth risk is **turning a research prototype into an unqualified diagnostic claim**. The 2024 Alzheimer’s criteria make clear that biomarker-based evaluation of cognitively unimpaired individuals is presently intended for research settings rather than routine clinical care. So frame the tool as a **research acceleration platform**, a **risk stratification engine**, or a **cohort enrichment tool**. That framing is scientifically accurate and much easier to defend. citeturn25view0

If you want one sentence to guide every design decision, use this: **build the most reliable longitudinal multimodal research tool you can, not the flashiest classifier you can demo**. That is the right reading of the challenge and the right reading of where the field’s evidence is strongest. citeturn7search0turn28view0

## Best suited GPT-5.5 high intelligence deep research prompt

Use this prompt as-is:

```text
Act as a top-tier biomedical AI strategy researcher and technical architect.

I need a deep-research report on the AI Challenge for Healthy Brain Aging focused on Alzheimer’s and dementia research. The challenge asks for AI models and tools such as prediction of development of mild cognitive impairment or dementia, models for disease progression, digital twins, and data processing / harmonisation tools. The data ecosystem includes public longitudinal resources like ADNI, UK Biobank, OASIS, ADDI, NACC, and AIBL, plus CBR’s Indian cohorts TLSA and SANSCOG. CBR-associated context also includes GenomeIndia and the YLOPD study.

My team profile:
- Bachelor of Technology graduates in Computer Science
- Specialisation in Bioinformatics
- Strong in Python, machine learning, data engineering, and basic genomics workflows
- Limited wet-lab capability
- Limited ability to train massive raw-image foundation models from scratch
- Need a realistic, high-impact, competition-ready plan

Deliver a thorough report in English with rich citations from official sources, major cohort websites, recent peer-reviewed papers, and high-quality clinical/biomedical guidance.

What I want you to produce:
- A sharp interpretation of what this challenge is really asking for
- A ranked brainstorm of the best project directions for my team
- A clear recommendation of the single best flagship project
- A deep dive into why that project is the best fit technically, scientifically, and strategically
- A dataset-by-dataset analysis covering ADNI, UK Biobank, OASIS, ADDI, NACC, AIBL, TLSA, SANSCOG, GenomeIndia, and YLOPD
- For each dataset, explain what it is best used for in this challenge and what not to use it for
- A practical multimodal modelling blueprint using structured MRI, OCT/OCTA, cognitive, blood biochemistry, and omics data
- A plan for harmonisation across cohorts
- A plan for progression modelling, risk prediction, and a feasible “digital twin lite” approach
- A section on genomics and how GenomeIndia changes the design for Indian cohorts
- A section on evaluation: external validation, calibration, survival metrics, subgroup fairness, interpretability, uncertainty, leakage prevention
- A section on what judges will likely value most
- A section on what to avoid because it is too ambitious, weakly validated, or not suited to a student team
- A 12-week execution roadmap with team roles, milestones, and deliverables
- A final section called “Winning Build Recommendation” with the exact proposed project name, scope, system architecture, novelty angle, demo plan, and minimum viable version

Important constraints:
- Prioritise feasible builds for a student team
- Optimise for scientific credibility and competition strength, not just novelty
- Do not recommend a vague chatbot or generic LLM assistant as the core project
- Treat raw-image foundation training as a stretch goal unless strongly justified
- Be explicit about where evidence is strong, weak, or still emerging
- Separate near-term build ideas from long-term frontier ideas
- When giving recommendations, make one clear call instead of many equal options
- Use recent sources wherever recency matters
- Prefer official cohort sources, consortium pages, and primary literature
- Cite every important claim

Format:
- Title
- Executive recommendation
- Dataset landscape
- Ranked project ideas
- Deep dive on the best flagship project
- Technical architecture
- Validation and judging risks
- Execution roadmap
- Winning Build Recommendation
- Appendix: tool stack, libraries, repo structure, and benchmark checklist
```

